寺岡 雄吏YUJI TERAOKA

Last Updated :2022/04/05

所属・職名
病院（医）　助教
メールアドレス
teraoka22hiroshima-u.ac.jp
自己紹介
消化器・代謝内科学にて主に肝臓の基礎研究を行っています。また、実習活動等を通して、医学生への指導を行っています。よろしくお願いいたします。

基本情報

学歴

  • 広島大学, 大学院医歯薬保健学研究科, 日本, 2016年04月, 2019年09月

学位

  • 博士（医学）　(広島大学)

研究分野

  • 医歯薬学 / 内科系臨床医学 / 消化器内科学
  • 医歯薬学 / 基礎医学 / ウイルス学

研究キーワード

  • 肝炎ウイルス、肝細胞癌

所属学会

  • 日本内視鏡学会 内視鏡専門医
  • 日本肝臓学会　肝臓専門医
  • 日本消化器病学会　消化器病専門医
  • 日本内科学会　総合内科専門医

教育活動

授業担当

  1. 2022年, 学部専門, 通年, 器官・システム病態制御学I
  2. 2022年, 学部専門, 集中, 臨床実習入門プログラム
  3. 2022年, 学部専門, 集中, 臨床実習I
  4. 2022年, 学部専門, 集中, 臨床実習II

研究活動

学術論文（★は代表的な論文）

  1. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice, Biochemical and Biophysical Research, 500巻, pp. 152-157, 2018
  2. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure, Journal of General Virology, 99巻, pp. 1058-1065, 2018
  3. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma, Hepatology Research, 48巻, pp. 193-204
  4. 胆管細胞癌における造影超音波検査所見の検討, 肝臓, 58巻, pp. 654-663
  5. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13巻, 2号, pp. 267-270, 202004
    DOIを用いた論文検索結果へのリンク
  6. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12巻, 202005
    DOIを用いた論文検索結果へのリンク
  7. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection, JOURNAL OF CLINICAL INVESTIGATION, 130巻, 6号, pp. 3205-3220, 20200601
    DOIを用いた論文検索結果へのリンク
  8. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 11巻, 202005
  9. Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion, Nat Microbiol
  10. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis, Hepatol Commun . 2019 Jan 22;3(3):348-355
  11. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis, Hepatol Res . 2018 Jan;48(1):51-58.
  12. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice, J Gen Virol . 2019 Jul;100(7):1123-1131.
  13. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection, J Clin Invest . 2020 Jun 1;130(6):3205-3220.
  14. Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring, PLoS One . 2018 Apr 3;13(4):e0195028.
  15. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma, Hepatol Res . 2018 Dec;48(13):1118-1130.
  16. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, J Gastroenterol . 2018 Jan;53(1):161-162.
  17. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy, J Med Virol . 2019 Apr;91(4):650-658.
  18. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury, J Gastroenterol . 2017 Dec;52(12):1252-1257.
  19. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis, Hepatol Res . 2018 Mar;48(4):264-274.
  20. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy, PLoS One . 2017 Aug 10;12(8):e0182710.
  21. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib, Oncology . 2017;92(6):335-346.
  22. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients, J Med Virol . 2017 Nov;89(11):1963-1972.
  23. Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction, J Med Virol . 2017 Apr;89(4):665-671.
  24. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients, Hepatol Res . 2020 Aug 6.
  25. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis, Hepatol Res . 2020 Sep 11.

招待講演、口頭・ポスター発表等

  1. 日本消化器病学会総会, 2019年, 日本語
  2. American Association for the Study of Liver Diseases(AASLD2018), 通常, 英語, San Francisco
  3. American Association for the Study of Liver Diseases(AASLD2019), 2019年, 通常, 英語

受賞

  1. 2019年, 日本肝臓学会 研究奨励賞, 日本肝臓学会
  2. 2014年11月08日, Young Investigator Award, 日本内科学会

外部資金

競争的資金等の採択状況

  1. ウイルス肝炎研究財団研究助成事業（研究奨励金）, ヒト肝細胞および免疫細胞を有するB型慢性肝炎モデルマウスの作成
  2. 土谷記念医学振興基金, B型肝炎ウイルス感染培養細胞およびモデルマウスを用いたcccDNAの制御および排除を目指した治療法の探索